It is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as confirmed by the MHRA's Product Information search and the Electronic Medicines Compendium (emc) nor by the European Medicines Agency (EMA) , and no European Public Assessment Report (EPAR) exists for this medicine
The additional glucagon receptor activity in retatrutide produces greater weight loss and more dramatic liver fat reduction
Packer M, Zile MR, Kramer CM, et al Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Non-elderly adults who are obese make up the largest share of those clinically eligible in the private insurance market: 45.8 million people or 80% of those indicated as possibly eligible in the private market are obese, of which 41.8 million people are indicated based on obesity alone
Now, that may be easier said than done
There are many reasons why someone might want to try GLP-1 microdosing